Securian Asset Management Inc. Sells 100 Shares of Masimo Co. (NASDAQ:MASI)

Securian Asset Management Inc. decreased its stake in Masimo Co. (NASDAQ:MASI) by 2.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,333 shares of the medical equipment provider’s stock after selling 100 shares during the period. Securian Asset Management Inc.’s holdings in Masimo were worth $551,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its holdings in shares of Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 60 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 64 shares in the last quarter. Blue Trust Inc. increased its position in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 71 shares in the last quarter. CIBC Asset Management Inc increased its holdings in shares of Masimo by 5.6% in the fourth quarter. CIBC Asset Management Inc now owns 1,631 shares of the medical equipment provider’s stock valued at $270,000 after purchasing an additional 87 shares in the last quarter. Finally, MML Investors Services LLC raised its position in shares of Masimo by 4.9% during the third quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock worth $274,000 after acquiring an additional 96 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Piper Sandler boosted their price target on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Raymond James upped their price target on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Finally, Wells Fargo & Company raised their price objective on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $194.80.

Masimo Stock Up 2.7 %

MASI stock opened at $172.78 on Tuesday. The firm has a market capitalization of $9.32 billion, a PE ratio of 119.16 and a beta of 1.04. The business’s 50 day simple moving average is $174.86 and its 200 day simple moving average is $158.33. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $194.88. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. As a group, research analysts anticipate that Masimo Co. will post 4.1 EPS for the current year.

Insider Activity at Masimo

In other news, COO Bilal Muhsin sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now owns 16,581 shares of the company’s stock, valued at $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by corporate insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.